DaVita HealthCare (DVA) Ascends But Remains Behind Market: Some Facts to Note

16.01.25 00:15 Uhr

Werte in diesem Artikel
Aktien

160,50 EUR -0,90 EUR -0,56%

755,00 JPY -80,00 JPY -9,58%

Indizes

5.996,7 PKT 59,3 PKT 1,00%

In the latest trading session, DaVita HealthCare (DVA) closed at $162.36, marking a +0.22% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 1.83%. Elsewhere, the Dow saw an upswing of 1.65%, while the tech-heavy Nasdaq appreciated by 2.45%.Shares of the kidney dialysis provider witnessed a gain of 9.78% over the previous month, beating the performance of the Medical sector with its loss of 3.48% and the S&P 500's loss of 3.31%.The investment community will be closely monitoring the performance of DaVita HealthCare in its forthcoming earnings report. The company is expected to report EPS of $2.21, up 18.18% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $3.25 billion, indicating a 3.47% growth compared to the corresponding quarter of the prior year.It is also important to note the recent changes to analyst estimates for DaVita HealthCare. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the company's business health and profitability.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, DaVita HealthCare holds a Zacks Rank of #1 (Strong Buy).From a valuation perspective, DaVita HealthCare is currently exchanging hands at a Forward P/E ratio of 14.41. For comparison, its industry has an average Forward P/E of 21.37, which means DaVita HealthCare is trading at a discount to the group.Meanwhile, DVA's PEG ratio is currently 0.79. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Medical - Outpatient and Home Healthcare industry held an average PEG ratio of 1.88.The Medical - Outpatient and Home Healthcare industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 38% echelons of all 250+ industries.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.You can find more information on all of these metrics, and much more, on Zacks.com.Free Today: Profiting from The Future’s Brightest Energy SourceThe demand for electricity is growing exponentially. At the same time, we’re working to reduce our dependence on fossil fuels like oil and natural gas. Nuclear energy is an ideal replacement.Leaders from the US and 21 other countries recently committed to TRIPLING the world’s nuclear energy capacities. This aggressive transition could mean tremendous profits for nuclear-related stocks – and investors who get in on the action early enough.Our urgent report, Atomic Opportunity: Nuclear Energy's Comeback, explores the key players and technologies driving this opportunity, including 3 standout stocks poised to benefit the most.Download Atomic Opportunity: Nuclear Energy's Comeback free today.Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DaVita Inc. (DVA): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf DaVita HealthCare Partners

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf DaVita HealthCare Partners

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu DaVita HealthCare Partners Inc

Wer­bung

Analysen zu DaVita HealthCare Partners Inc

DatumRatingAnalyst
03.01.2019DaVita HealthCare Partners BuyDeutsche Bank AG
14.12.2018DaVita HealthCare Partners OverweightBarclays Capital
12.12.2017DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
08.11.2017DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.12.2016DaVita HealthCare Partners NeutralRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
03.01.2019DaVita HealthCare Partners BuyDeutsche Bank AG
14.12.2018DaVita HealthCare Partners OverweightBarclays Capital
12.12.2017DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
27.04.2015DaVita HealthCare Partners OutperformRobert W. Baird & Co. Incorporated
18.10.2011DaVita outperformRobert W. Baird & Co. Incorporated
DatumRatingAnalyst
08.11.2017DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.12.2016DaVita HealthCare Partners NeutralRobert W. Baird & Co. Incorporated
04.11.2015DaVita HealthCare Partners Sector PerformRBC Capital Markets
06.08.2015DaVita HealthCare Partners Sector PerformRBC Capital Markets
13.03.2015DaVita HealthCare Partners HoldDeutsche Bank AG
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für DaVita HealthCare Partners Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"